The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by re-inventing the treatment pathway for patients.
The MFICM hosted at the University of Cambridge aims to revolutionise cancer care by using cutting edge analytics to maximise the use of diverse, high-volume data sets. The virtual institute exploits recent advances in machine learning and big data technology to capture, integrate, and derive insight from clinical, genomic and imaging data collated from hundreds of cancer patients in real time. Laboratory, clinic-based researchers, and data experts are working together to develop sophisticated computational integration of these diverse data types into a single platform which can inform and predict the best treatment decisions for each individual patient.
The MFICM includes the critical individuals and technologies needed to deliver a revolutionary new cancer treatment paradigm. During the course of the initial three-year funding, this paradigm will be applied to manage patients with breast cancer as part of the PARTNER and PARTNERING clinical trials and the PBCP translational study. It has also been extended to the WIRE trial in renal, the OV04 translational study in ovarian, the ATRiUM trial in pancreatic cancer, as well as the DIRECT trial in B-cell Lymphoma. Longitudinal Data Streams will be integrated that simultaneously report the functional biology of tumours among cancer patients receiving active treatment.
The continual, iterative and integrated analysis of these complementary, complex data streams – made possible by advanced machine learning and other computational approaches – will enable a new decision matrix for optimal cancer treatment selection and improved chance of cure.
To view the MFICM website in full please click on the "Find out more" button below.
The MFICM unites 64 researchers and clinicians across a variety of departments within the University of Cambridge, Cambridge University Hospitals and beyond. It focuses on 5 main disease areas currently: breast, ovarian, renal, pancreatic and B-cell lymphoma and supports 7 prospective clinical trials/translational studies.
For more information on MFICM research including the ICM concept, disease areas, the prospective trials and studies, advanced cancer imaging, computational analysis and data integration as well as a full publication list, please click on the "Find out more" button below.
You will also find a link to the new ICM Research in Focus Podcast Series on the Thought Leadership page.
The Mark Foundation Institute for Integrated Cancer Medicine has set up collaborations with 14 departments within the University of Cambridge, ranging from Radiology to the Computer Laboratory, Biochemistry and many more. To access a full directory of MFICM members please click on the "Find out more" button below.
MFICM members engage in a variety of public facing events as well as the MFICM research attracting media coverage in a variety of different publications/digital resources. For full details about the latest MFICM News and Events please click on the "Find out more" button below.
The Foundation supports cutting-edge, innovative scientific ideas that will answer the most complex questions about cancer biology and lead to new and better ways to prevent, diagnose, and treat the disease. The Foundation was established by Alex Knaster and is led by Michele Cleary, PhD. It has funded over 100 grants in 50 institutions globally in 6 different countries.
The Mark Foundation for Cancer Research is dedicated to accelerating cures for cancer by integrating discoveries in biology with innovative technology. The Foundation pursues its mission by funding a global portfolio of ground-breaking research carried out by individual investigators, multi-investigator teams, and inter-institutional collaborations.